Genetic Technologies' BrevaGen
This article was originally published in The Gray Sheet
Executive Summary
Breast cancer risk test is acquired through an asset purchase deal with Perlegen Sciences for undisclosed terms. Announced April 14, the deal will allow Genetic Technologies to launch the test in the U.S. and Australia in the second half of 2010, the firm says. The test combines population risk factors based on the Gail Score with validated genetic risk factors to measure non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate, the company explains. "This product fulfils an unmet need by better classifying women at moderate risk of breast cancer who would potentially benefit from preventive therapy or more intensive monitoring." The firm estimates the potential U.S. market at up to $400 million-$500 million